Phase 1, Single Dose Study to evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

Exclusion Criteria

• -Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product
• - History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
• -Abnormal lab values, physical exam, vital signs
• -Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks prior to dosing
• -Positive Hepatitis B, Hepatitis C or HIV test
• -Receipt of investigational therapy with 4 months from screening
• -Current or previous use of systemic corticosteroids 60 days prior to dosing or lipid lowering medications 28 days prior to dosing
• -Abnormal ECG
• -Recent plasma or blood donation
• -Positive drug or alcohol screen.
• -Current smoker